Cybin (CYBN) Receives a Buy from H.C. Wainwright
In a report released today, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Cybin, with a price target of $55.00.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Trucchio covers the Healthcare sector, focusing on stocks such as Precision BioSciences, Aligos Therapeutics, and Altimmune. According to TipRanks, Trucchio has an average return of 34.3% and a 52.91% success rate on recommended stocks.
Cybin has an analyst consensus of Strong Buy, with a price target consensus of $45.00.
CYBN market cap is currently C$1.92M and has a P/E ratio of -0.02.
Read More on CYBN:
Disclaimer & DisclosureReport an Issue
- Cybin to Rebrand as Helus Pharma and Shift U.S. Listing to Nasdaq
- Jefferies sees potential tailwind forming for psychedelics from marijuana shift
- Cybin to transfer U.S. stock exchange listing to Nasdaq
- Psychedelic: Clearmind completes second cohort enrollment for CMND-100 trial
- Cybin to Shift U.S. Listing to Nasdaq and Rebrand Ticker as HELP
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.